Topic Hub
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 8 of 8 clinical reviews.
A clinical breakdown of isotretinoin's compounding restrictions under federal law, the iPLEDGE REMS program, FDA enforcement history, and what the current label requires for prescribers and patients.
Read clinical reviewA detailed review of isotretinoin (Accutane) safety signals reported to the FDA Adverse Event Reporting System (FAERS), covering psychiatric events, IBD associations, teratogenicity monitoring through iPLEDGE, and what the post-market surveillance data mean for prescribers and patients.
Read clinical reviewComplete regulatory timeline of isotretinoin from its 1982 FDA approval through iPLEDGE implementation, generic entry, and ongoing post-market safety surveillance.
Read clinical reviewA comprehensive review of isotretinoin's regulatory history across the FDA, EMA, and international agencies, including iPLEDGE REMS requirements, label updates, and post-market safety surveillance.
Read clinical reviewA complete clinical reference covering every FDA label change, iPLEDGE revision, and post-market safety signal for isotretinoin from 2020 through 2026, with primary-source citations throughout.
Read clinical reviewA clinical review of isotretinoin's regulatory history, current FDA label requirements, iPLEDGE program updates, next-generation retinoid pipeline candidates, and post-market safety surveillance data.
Read clinical reviewA detailed comparison of how the FDA and EMA regulate isotretinoin, covering iPLEDGE vs Pregnancy Prevention Programme, label differences, post-market surveillance, and what each framework means for patients and prescribers.
Read clinical reviewA detailed look at isotretinoin's FDA approval history, patent expirations, product liability litigation, iPLEDGE regulatory requirements, and ongoing safety monitoring.
Read clinical review